Spots Global Cancer Trial Database for multiple myeloma, refractory
Every month we try and update this database with for multiple myeloma, refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT05121103 | Multiple Myelom... Diffuse Large B... Diffuse Large B... Multiple Myelom... | EZM0414 | 18 Years - | Ipsen | |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | NCT05739188 | Multiple Myelom... Multiple Myelom... | Anti-GPRC5D CAR... | 18 Years - 75 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors | NCT06411301 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | 225Ac-DOTATATE | 18 Years - | Jules Bordet Institute | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02176213 | Multiple Myelom... Multiple Myelom... | Pomalidomide Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment | NCT04811898 | Multiple Myelom... Hepatocarcinoma Advanced Solid ... | LNA-i-miR-221 | 18 Years - | Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | |
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | NCT06242249 | Multiple Myelom... | Anti-BCMA CAR-N... | 18 Years - 80 Years | Shahid Beheshti University of Medical Sciences | |
| Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | NCT05493618 | Multiple Myelom... | Pembrolizumab Belantamab mafo... Dexamethasone | 18 Years - | Hackensack Meridian Health | |
| Alvocade® (Bortezomib) Safety and Effectiveness Study | NCT06012383 | Multiple Myelom... | Bortezomib | - | NanoAlvand | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | NCT06225310 | Multiple Myelom... Multiple Myelom... | Selinexor Ruxolitinib Methylprednisol... | - | Oncotherapeutics | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Recurrent Plasm... Refractory Plas... | Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | NCT04861480 | Multiple Myelom... Multiple Myelom... | C-4-29 Cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors | NCT06411301 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | 225Ac-DOTATATE | 18 Years - | Jules Bordet Institute | |
| Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | NCT05008536 | Multiple Myelom... | Anti-BCMA CAR-N... Fludarabine Cytoxan | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | NCT05909826 | Multiple Myelom... Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 19 Years - | Dong-A University Hospital | |
| A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies | NCT05836896 | Neoplasms Relapsed Diffus... Refractory Diff... Multiple Myelom... Multiple Myelom... | MDC-CAR-BCMA001... | 18 Years - | Technische Universität Dresden | |
| Alvocade® (Bortezomib) Safety and Effectiveness Study | NCT06012383 | Multiple Myelom... | Bortezomib | - | NanoAlvand | |
| Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | NCT04813653 | Multiple Myelom... Multiple Myelom... | cyclosporine in... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies | NCT05836896 | Neoplasms Relapsed Diffus... Refractory Diff... Multiple Myelom... Multiple Myelom... | MDC-CAR-BCMA001... | 18 Years - | Technische Universität Dresden | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Recurrent Plasm... Refractory Plas... | Pembrolizumab | 18 Years - | University of California, San Francisco | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | NCT06225310 | Multiple Myelom... Multiple Myelom... | Selinexor Ruxolitinib Methylprednisol... | - | Oncotherapeutics | |
| Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | NCT05495620 | Multiple Myelom... Multiple Myelom... | Carfilzomib Lenalidomide Dexamethasone | 19 Years - | Dong-A University Hospital | |
| Marizomib Central Nervous System (CNS) | NCT05050305 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | Marizomib Pomalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | NCT05008536 | Multiple Myelom... | Anti-BCMA CAR-N... Fludarabine Cytoxan | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | NCT05673083 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... | 18 Years - | All4Cure | ||
| A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | NCT04688853 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | TEG002 | 18 Years - | Gadeta B.V. | |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT05121103 | Multiple Myelom... Diffuse Large B... Diffuse Large B... Multiple Myelom... | EZM0414 | 18 Years - | Ipsen | |
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | NCT06242249 | Multiple Myelom... | Anti-BCMA CAR-N... | 18 Years - 80 Years | Shahid Beheshti University of Medical Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
